Human thrombin
Package labels
Loading package label images…
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Human Blood Coagulation Factor
Dosing in kidney impairment
This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.
Preparation and administration
Prepare this dose
Your numbers for human thrombin. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Reconstitution Prior to Application Reconstitute the lyophilized human thrombin powder. Use aseptic technique when handling vials and syringes. Remove the flip-off plastic cap from the vial to expose the rubber stopper. Using a sterile needle and syringe, add 2 ml of Water for Injection, USP to the glass vial. Shake gently until the solution is clear.
Reconstituted solution is stable for up to 8 hours at room temperature and should be used within this time period.
Drug interactions
Check interactions
Add the patient's other drugs. Matches come from both FDA labels: by name, drug class, and enzyme or transporter pathway.
- Human thrombin
Label text (1 paragraph)
No drug interactions are known.
Contraindications
Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products. Do not use for the treatment of severe or brisk arterial bleeding. Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products ( 4 ). Do not use for treatment of severe or brisk arterial bleeding ( 4 ).
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for human thrombin. Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Teratogenic effects: Pregnancy category C Adequate and well-controlled studies in pregnant women have not been performed. EVITHROM should be used in pregnancy only if the potential benefit to the pregnant woman justifies the potential risk to the fetus. Studies to evaluate the potential reproductive/developmental toxicity of EVITHROM have not been performed due to the human origin of thrombin. However, studies to evaluate the potential reproductive/developmental toxicity of residual levels of Triton X-100 and tri-n-butyl phosphate (solvent/detergent reagents) were conducted in animals and are summarized in the Non Clinical Toxicology section ( 13 ).
Lactation
8.3 Nursing Mothers The safety of EVITHROM for use during breast-feeding has not been established. Use only if clearly needed.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.